Analysis to be Presented Showed Peanut Allergy Treatment with PALFORZIA was Associated with Improvements in Health-Related Quality of Life among Patients and Caregivers -Additional Data to be Presented
Consumer News
Jan 11, 2021 11:53 AM By Sabrina Emms A new enzyme treatment is being used to develop hypoallergenic peanuts. Photo courtesy of Shutterstock
Harmless to some but anything but to others, a peanut allergy is a big deal. Around 2% of children have allergies to peanuts, which is one of eight recognized major food allergens.
In January 2020, pre-Covid, the FDA approved a drug to treat peanut allergies in children. Called Palforzia, it isn’t a traditional drug, but instead a peanut allergen powder made of peanut powder and peanut protein. Palforzia conditions the immune system to tolerate peanuts in very very small doses over three phases of administration. But, with that comes the risk of allergic reactions during treatment. Of 709 treated trial participants, severe reactions were reported in 9.4% participants in the first two phases, as opposed to nearly 4% of the 292 who were not treated. The children in the placebo group were not exposed to�